Microbot Medical Inc.

Equities

MBOT

US59503A2042

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 07/06/2024 BST 5-day change 1st Jan Change
1.08 USD -6.09% Intraday chart for Microbot Medical Inc. +8.00% -34.15%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Gain Late Afternoon MT
Microbot Gets FDA Nod to Start Trial, to Raise $2.35 Million From Direct Offering Deal; Shares Soar MT
Top Midday Gainers MT
Microbot Medical Inc. Has Received FDA Approval to Proceed with Its Pivotal Human Clinical Trial CI
Microbot Medical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Microbot Medical Announces Positive Results from the First Phase of Its Collaboration with Corewell Health CI
HC Wainwright Adjusts Microbot Medical's Price Target to $7 From $8, Keeps Buy Rating MT
Microbot Medical Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Microbot Medical Submits US FDA Application to Start Human Clinical Trial for Robotic Surgical System MT
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US CI
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study CI
Sector Update: Health Care Stocks Ease Friday Afternoon MT
Microbot Medical to Exercise Outstanding Preferred Investment Options for $2.7 Million MT
Sector Update: Health Care Stocks Rise in Late Afternoon MT
Microbot Medical Says GLP Preclinical Study of Liberty Endovascular Robotic Surgical System Met Objectives; Shares Rise MT
Sector Update: Health Care Stocks Advance Thursday Afternoon MT
Microbot Medical Announces Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Met CI
Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY Endovascular Robotic Surgical System for Telerobotic CI
Microbot Medical Announces the Successful Completion of its GLP Pivotal Pre-Clinical Study CI
Microbot Medical Inc. Announces Executive Changes CI
Microbot Medical Files $75 Million Shelf MT
Microbot Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Microbot Medical Inc. Successfully Completed Integral Part of the Verification and Validation Process CI
Sector Update: Health Care Stocks Mixed Late Wednesday Afternoon MT
Sector Update: Health Care Stocks Lower in Afternoon Trading MT
Chart Microbot Medical Inc.
More charts
Microbot Medical Inc. is a pre-clinical medical device company. The Company is specializing in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. It is primarily focused on leveraging its robotic technologies with surgical robotics to improve surgical outcomes for patients. Its technological platforms include LIBERTY and NovaCross. Using its LIBERTY Endovascular Robotic Surgical System, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. LIBERTY Endovascular Robotic Surgical System addresses the needs of interventional cardiology, interventional radiology and interventional neuroradiology markets.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.08 USD
Average target price
7 USD
Spread / Average Target
+548.15%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. MBOT Stock
  4. News Microbot Medical Inc.
  5. Microbot Medical Names Rachel Vaknin CFO
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW